Sheryl F Vondracek
Overview
Explore the profile of Sheryl F Vondracek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
152
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vondracek S, Teitelbaum I, Kiser T
Am J Kidney Dis
. 2021 Jul;
78(3):442-458.
PMID: 34275659
Medications are an important part of the management of patients with kidney disease. When used appropriately, pharmacotherapy can slow disease progression and reduce morbidity and mortality. Unfortunately, reduced kidney function...
2.
Scholl T, Kiser T, Vondracek S
Chronic Obstr Pulm Dis
. 2018 Apr;
5(1):57-65.
PMID: 29629405
Chronic obstructive pulmonary disease (COPD) and pneumonia are leading causes of morbidity and mortality and are frequently comorbid. Studies of systemic corticosteroids in pneumonia have shown conflicting outcomes, whereas studies...
3.
Shea K, Gavin K, Melanson E, Gibbons E, Stavros A, Wolfe P, et al.
Menopause
. 2015 Mar;
22(10):1045-52.
PMID: 25783468
Objective: Suppression of ovarian hormones in premenopausal women on gonadotropin-releasing hormone agonist (GnRH(AG)) therapy can cause fat mass (FM) gain and fat-free mass (FFM) loss. Whether this is specifically caused...
4.
Vande Griend J, McQueen R, Linnebur S, Vondracek S
Pharmacotherapy
. 2012 Mar;
32(2):135-41.
PMID: 22392422
Study Objectives: To determine the efficacy and safety of vitamin D repletion with prescription ergocalciferol and to determine patient-specific factors that may influence the amount of ergocalciferol needed to attain...
5.
Vondracek S, Hoody D
Ann Pharmacother
. 2011 Jul;
45(7-8):1011-5.
PMID: 21750312
Objective: To review the data supporting combination therapy with vitamin D and vitamin D receptor activators (VDRAs) in patients with stage 5 chronic kidney disease (CKD). Data Sources: Literature was...
6.
Vondracek S
Am J Health Syst Pharm
. 2010 Mar;
67(7 Suppl 3):S9-19.
PMID: 20332498
Purpose: To describe strategies used in managing postmenopausal osteoporosis, including a bone-healthy lifestyle, adequate calcium and vitamin D intake, and drug therapy options; considerations in selecting osteoporosis drug therapy; and...
7.
Vondracek S, Voelkel N, McDermott M, Valdez C
Int J Chron Obstruct Pulmon Dis
. 2009 Aug;
4:267-77.
PMID: 19657401
Osteoporosis is common in patients with chronic obstructive pulmonary disease (COPD). Data regarding the relationship between adipokines and bone mineral density (BMD) in this population is lacking. The purpose of...
8.
Vondracek S, Linnebur S
Clin Interv Aging
. 2009 Jun;
4:121-36.
PMID: 19503775
The older senior is at high risk for osteoporosis. It is important for healthcare providers to be fully aware of the potential risks and benefits of diagnosing and treating osteoporosis...
9.
Vondracek S, Hansen L, McDermott M
Pharmacotherapy
. 2009 Mar;
29(3):305-17.
PMID: 19249949
Although clinically significant bone loss and fractures in healthy premenopausal women are rare, more women are seeking evaluation for osteoporosis from their health care providers. As pharmacists are in an...
10.
Vondracek S, Minne P, McDermott M
Clin Interv Aging
. 2008 Aug;
3(2):315-29.
PMID: 18686753
While knowledge regarding the diagnosis and treatment of osteoporosis has expanded dramatically over the last few years, gaps in knowledge still exist with guidance lacking on the appropriate management of...